Company intelligence / Profile preview

Tiltan Pharma

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Tiltan Pharma has developed a proprietary anti-angiogenic and immune modulatory platform for the treatment of cancer. Its lead programs are in clinical development for pancreatic cancer and castration-resistant prostate cancer. The company’s main asset, TL-118, targets H2 receptor and NFKB2 pathways. Another program involves a combination therapy targeting COXs and H2 receptor for pancreatic cancer. Both are at pending/clinical stages with no reported approvals as of June 2025.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

TL-118

Partnerships

Not specified in available sources.

Beyond the preview

Go deeper on Tiltan Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiltan Pharma.